Akero First To Show Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.

3D illustration of many arrows symbols pointing in the same direction and one arrow going back. Concept of regression.
In a small sample, Akero's EFX showed an ability to reverse cirrhosis in NASH patients

More from Clinical Trials

More from R&D